Pharvaris, N.V (PHVS)
| Market Cap | 505.21M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 33.09M |
| EPS (ttm) | -4.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,784 |
| Open | 14.52 |
| Previous Close | 14.80 |
| Day's Range | 14.52 - 15.98 |
| 52-Week Range | 13.14 - 42.86 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 42.91 (+181.4%) |
| Est. Earnings Date | Oct 29, 2021 |
About PHVS
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks; and PHVS719, a prophylactic extended-release tablet for HAE patients. It operates in the Netherlands, Switzerland, and the United...
Analyst Forecast
According to 4 analysts, the average rating for Pharvaris stock is "Buy." The 12-month stock price forecast is 42.91, which is an increase of 181.38% from the latest price.
News
Pharvaris to Participate in Upcoming September Investor Conferences
ZUG, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists ...
Pharvaris Reports Second Quarter 2021 Financial Results and Provides Business Highlights
ZUG, Switzerland, July 30, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists f...
Pharvaris Presents Clinical Data on Oral PHA121 Supporting the Prophylactic Treatment of Hereditary Angioedema at the...
Multiple doses of PHA121 were well-tolerated and showed a favorable pharmacokinetic profile for prophylactic treatment of HAE Multiple doses of PHA121 were well-tolerated and showed a favorable pharmaco...
Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021
ZUG, Switzerland, July 01, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists f...
Pharvaris Announces Annual Meeting of Shareholders
ZUG, Switzerland, June 11, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists f...
Pharvaris Presents Pharmacokinetic and Pharmacodynamic Data for Oral PHA121, Under Development for the Treatment of H...
ZUG, Switzerland, June 04, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists f...
Pharvaris Reports First Quarter 2021 Financial Results and Provides Business Highlights
ZUG, Switzerland, May 26, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists fo...
Pharvaris Reports Full Year 2020 Financial Results and Provides Business Highlights
ZUG, Switzerland, April 29, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the ...
Pharvaris to Participate in BioCapital Europe
ZUG, Switzerland, March 04, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the ...
Pharvaris Doses First Patient in RAPIDe-1, a Phase 2 Study Evaluating PHVS416 for the On-Demand Treatment of HAE
ZUG, Switzerland, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the t...
Pharvaris Presents Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE, at the AAAAI ...
Single-dose treatment of PHA121 demonstrated effective bradykinin inhibition in healthy volunteers Single-dose treatment of PHA121 demonstrated effective bradykinin inhibition in healthy volunteers
Pharvaris Announces Closing of Initial Public Offering
ZUG, Switzerland, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris”) (Nasdaq: PHVS), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization o...
Pharvaris Announces Pricing of Upsized Initial Public Offering Nasdaq:PHVS
ZUG, Switzerland-- Pharvaris N.V. (“Pharvaris”), a clinical-stage biopharmaceutical company focused on the discovery,...
Pharvaris Announces Phase 1 Clinical Data of PHA121, an Oral B2 Receptor Antagonist Under Development for the Treatme...
Pharvaris Announces Phase 1 Clinical Data of PHA121, an Oral B2 Receptor Antagonist Under Development for the Treatment of Hereditary Angioedema.
Dutch rare disease biotech Pharvaris files for a $100 million US IPO
Pharvaris, a Dutch Phase 1 biotech developing small molecule therapies for rare diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Pharvaris IPO Registration Document (S-1)
Pharvaris, N.V has filed to go public with an IPO on the NASDAQ.